• Molecular NameAlfuzosin
  • SynonymAlfusosine; alfuzosin
  • Weight389.456
  • Drugbank_IDDB00802
  • ACS_NO81403-80-7
  • Show 3D model
  • LogP (experiment)1.604
  • LogP (predicted, AB/LogP v2.0)1.48
  • pka8.1
  • LogD (pH=7, predicted)0.86
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-1.68
  • LogSw (predicted, AB/LogsW2.0)0.47
  • Sw (mg/ml) (predicted, ACD/Labs)0.46
  • No.of HBond Donors3
  • No.of HBond Acceptors9
  • No.of Rotatable Bonds8
  • TPSA111.83
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn α1 receptor antagonist used to treat benign prostatic hyperplasia (BPH).
  • Absorption_valueN/A
  • Absorption (description)Alfuzosin is readily absorbed after oral administration.
  • Caco_2N/A
  • Bioavailability55.0
  • Protein binding86.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmAlfuzosin undergoes extensive metabolism by the liver, with only 11% of the administered dose excreted unchanged in the urine. Alfuzosin is metabolized by three metabolic pathways: oxidation, O-demethylation, and N-dealkylation. The metabolites are not pharmacologically active. CYP3A4 is the principal hepatic enzyme isoform involved in its metabolism.
  • Half life10 h,Plasma, 3~5 h
  • ExcretionFecal (69%) and renal (24%)
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySide effects include dizziness (due to postural hypotension), upper respiratory tract infection, headache, and fatigue.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A